CLINICAL TRIAL: THE EFFECTS OF TESTOSTERONE AND ACTONEL ON BONE DENSITY IN ANORE

临床试验：睾酮和 Actonel 对肛门骨密度的影响

• 批准号: 7731240
• 负责人: ANNE KLIBANSKI
• 金额: $ 2.2万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731240
• 关键词: Adrenal Glands; Anorexia Nervosa; Bone Density; Cells; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Eating Disorders; Fracture; Funding; Grant; Hormones; Institution; Maintenance; Muscle; Osteoblasts; Osteogenesis; Osteoporosis; Osteoporosis prevention; Ovary; Pharmaceutical Preparations; Physiological; Postmenopause; Purpose; Research; Research Personnel; Resources; Risedronate; Source; Testosterone; United States National Institutes of Health; Woman; bone; men; risedronate sodium

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Anorexia nervosa is an eating disorder that can cause thinning of the bones (a decrease in bone density). A significant decrease in bone density is called osteopenia or osteoporosis. Sometimes the loss of bone density can be severe enough to cause breaks and fractures of the bones. It is not known what causes the bones to thin in anorexia nervosa. The purpose of the study is to evaluate the effects of two different medications, physiologic testosterone replacement and risedronate, on bone density in subjects with anorexia nervosa. Testosterone is a hormone that is made by the ovaries and adrenal glands in both women and men and has been shown to be important for prevention of osteoporosis and maintenance of muscle mass in men. Testosterone has been shown to stimulate bone forming cells called osteoblasts, and to increase bone formation and bone density in post-menopausal women, but its effects on bone formation or bone density in women with anorexia nervosa are not known. Actonel is a medication that is prescribed for low bone density to postmenopausal women.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 神经性厌食症是一种进食障碍，可导致骨骼变薄(骨密度下降)。骨密度的显著下降称为骨量减少或骨质疏松。有时，骨密度的丧失可能会严重到足以导致骨骼断裂和骨折。目前尚不清楚是什么原因导致神经性厌食症患者的骨骼变薄。本研究的目的是评估两种不同的药物--生理性睾酮替代疗法和利塞膦酸对神经性厌食症患者骨密度的影响。睾酮是一种荷尔蒙，由女性和男性的卵巢和肾上腺产生，已被证明对预防男性骨质疏松症和维持肌肉质量非常重要。已有研究表明，睾酮可以刺激称为成骨细胞的骨形成细胞，并增加绝经后女性的骨形成和骨密度，但它对患有神经性厌食症的女性的骨形成或骨密度的影响尚不清楚。Actonel是一种针对绝经后妇女骨密度低的药物。